Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SARS-CoV-2 Spike protein S2 subunit is a class I viral fusion protein subunit responsible for mediating the fusion between the viral envelope and the host cell membrane (UniProt: P0DTC2). It contains several highly conserved functional elements, including the fusion peptide (FP), heptad repeats 1 and 2 (HR1 and HR2), and a transmembrane domain (PubMed: 32221306). Following the binding of the S1 subunit to the ACE2 receptor and subsequent proteolytic cleavage at the S2' site, the S2 subunit undergoes a dramatic conformational rearrangement to form a post-fusion six-helix bundle (6HB), which pulls the viral and host membranes together (Nature: 10.1038/s41586-020-2179-y). Because the S2 domain is significantly more conserved across various coronavirus strains than the S1 domain, it is a primary target for the development of broad-spectrum (pan-coronavirus) vaccines and fusion inhibitor therapies (Science: 10.1126/science.abj8322). Therapeutic agents like the EK1 peptide and its derivatives target the HR1 region to prevent the HR1-HR2 interaction, effectively blocking viral entry across multiple variants (Cell: 10.1016/j.cell.2020.03.031).
Inhibition of viral-host membrane fusion by binding to the heptad repeat 1 (HR1) region or the stem helix, preventing the formation of the six-helix bundle (6HB) required for viral entry (Cell: 10.1016/j.cell.2020.03.031; Science: 10.1126/science.abj8322).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Severe acute respiratory syndrome coronavirus 2 Spike protein S2 subunit (S2) (S2).